To view or add a comment, sign in Genentech Reports the US FDA's Approval of Gazyva (Obinutuzumab) to Treat Lupus Nephritis #genentech #gazyva #obinutuzumab #lupusnephritis #usfda #regulatory #monoclonalantibody #nobility #regency #pii #piii #ro5072759 #rg7159 #r7159 #ga101 To view or add a comment, sign in Potential future royalty income from Metsera/Pfizer* obesity drug candidates As highlighted in our 2025 half-yearly results, IP Group has financial exposure to several of Metseras obesity drug programmes, following its acquisition of our former portfolio company Zihipp Limited in 2023
Several drugs, including para-aminosalicylic acid, have been reported to reduce the absorption of methylcobalamin, vitamin B12
Secondary outcome measurements included reduction in body weight from baseline by at least 5% or 10% by week 26, changes in waist circumference, total cholesterol, HDL, LDL, VLDL, and triglycerides, and levels of different glycemic variables including HbA1C, fasting plasma glucose, fasting insulin, insulin resistance, and the functioning of beta-cells
no brindan orientacin sobre seguridad o eficacia
